Ameera-3: Amcenestrant Does Not Improve Pfs In Er+/Her2- Breast Cancer

AMEERA-3: amcenestrant does not improve PFS in ER+/HER2- breast cancer

AMEERA-3: SERD for ER+ HER2- breast cancer

AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancer

Patient eligibility in the AMEERA-6 trial of amcenestrant

AMEERA-1 updates: amcenestrant plus palbociclib for patients with ER+/HER2– advanced breast cancer

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

PeerView Oncology

AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer

Optimizing the Identification of HER2-Low Breast Cancer (Video Lecture)

Research To Practice

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancer

What EMERALD Phase III trial could mean for breast cancer patients | Virginia Kaklamani, MD

UT Health San Antonio MD Anderson Cancer Center

What does the future hold for SERDs in ER+ breast cancer?

Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer

Touch Medical Media Services

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

The History Of Breast Cancer Diagnosis, Subtypes And Treatment

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer

Revolutionizing HER2-Positive Breast Cancer Treatment: Unveiling Breakthrough Results!

Clinical Trials for Stage II-III Breast Cancer

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, Targets